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Solvent-free desymmetrisation of a meso-dialdehyde with chiral alcohols, led to preparation of 4-
silyloxy-6-alkyloxytetrahydro-2H-pyran-2-one derivatives with a 96% de. This methodology, which
yields the corresponding methyl nor-mevaldates with 99% ee, has been applied to the enantioselective
synthesis of the ()-(R) and (þ)-(S) nor-mevalonic acid lactones.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Enantioselective desymmetrisation of meso or prochiral com-
pounds has become a powerful tool in the preparation of enan-
tiomerically pure compounds,1 using chiral reagents, enzymes2 or
catalysts.3 Symmetrical or achiral precursors may provide a syn-
thetic advantage by permitting inclusion of a certain degree of
complexity before introducing chirality at the desymmetrisation
step, instead of incorporating chirality at very early steps of
a synthesis.
This approach has been successfully applied to the desym-
metrisation of a range of substrates such as dienes,4 meso-anhy-
drides,5 meso-diols6 and meso-dialdehydes. Desymmetrisation of
meso-dialdehydes has been performed via Hor-
nereWadswortheEmmons reaction,7 alkylation,8 carbonyl-ene
cyclisation reaction9 and aldol condensation, either using chiral
reagents,10 an organometallic catalyst11 or organocatalysis.12
In this respect, the synthetic utility of 1,3,5-trioxygenated sub-
strates has led to much interest in their enantiocontrolledx: þ34 956 016193; e-mail
hez).preparation.13 For instance, enantiomerically pure methyl nor-
mevaldate 1 has been used as a building block for the synthesis
of bioactive molecules such as b-hydroxyacids with antifungal ac-
tivity,14 HMG-CoA reductase inhibitors15 or analogues of statins16
and 6-alkyl-4-hydroxypyran-2-ones17 with oestrogenic activity.
Furthermore, diverse mevalonic lactone analogues with different
substituents in position 4 have been recently synthesised and re-
ported as inhibitors of the mevalonate pathway in the bacterium
Streptococcus pneumoniae.18
As part of our strategy for the design of antifungal agents against
Botrytis and Colletotrichum species,19 we have recently reported the
preparation of 4-hydroxy-6-(1-phenylethoxy)tetrahydro-2H-py-
ran-2-one (2) as a selective antifungal agent against the phyto-
pathogen Botrytis cinerea via the desymmetrisation reaction of
a suitable meso-dialdehyde precursor 3 with chiral
phenylethanol.20,21
In this paper we extend this methodology to the preparation of
a range of 6-alkyloxy-4-silyloxytetrahydro-2H-pyran-2-ones using
different chiral alcohols. The use of the dialdehyde 3 as a building
block for the enantioselective preparation of 1,3,5-trioxygenated
substrates related to methyl nor-mevaldate 1, such as nor-
mevalonic acid lactones ()-(R)-4 and (þ)-(S)-5 is also described
J.M. Botubol-Ares et al. / Tetrahedron 71 (2015) 7531e75387532(Fig. 1). These compounds are of interest for structureeactivity
relationship (SAR) studies.Fig. 1. Structures 1e5.2. Results and discussion
2.1. Optimisation of desymmetrisation reaction
The absolute stereochemistries of chiral 6-arylalkyloxy-4-
silyloxytetrahydro-2H-pyran-2-ones (þ)-6a and (þ)-6b were
established unequivocally in previous reports by a combination of
X-ray crystallographic analyses of the structurally related tetrahy-
dro-2H-pyran-2-ones (þ)-7a and ()-7c, NOE difference studies
and chemical correlation of tetrahydro-2H-pyran-2-ones (þ)-6a
and (þ)-7a with ()-(R) methyl 3-(tert-butyldimethylsilyloxy)-5-
oxopentanoate (8) and of tetrahydro-2H-pyran-2-ones (þ)-6b and
()-7c with (þ)-(S) methyl 3-(tert-butyldimethylsilyloxy)-5-
oxopentanoate 9 (Scheme 1).21Scheme 1. Chemical correlation of lactones (þ)-6a and (þ)-7a with compound
()-(R)-8 and of lactones (þ)-6b and ()-7c with (þ)-(S)-9.
Scheme 2. Solvent-free desymmetrisation of dialdehyde 3 with different chiral
alcohols.
Scheme 3. Preparation of ()-15a and ()-15b via solvent-free desymmetrisation of
dialdehyde 3 with ()-(S)-1-(naphthalen-2-yl)ethanol.Evaluation of the influence of the chiral alcohol structure on the
diastereoselectivity of the desymmetrisation process was then
undertaken. Consequently, solvent-free conditions,20 which havebeen shown to lead to better selectivity than the use of dry THF for
the preparation of lactone (þ)-6a,21 were applied to a series of
commercially available chiral alcohols 10e14, achieving an optimal
14.7% overall yield and 96% de with (þ)-(R) or ()-(S)-1-(naph-
thalen-2-yl)ethanol (Schemes 2 and 3, Table 1, entry 6). Best yields
and de were obtained when 1-arylethanols were used as chiral
auxiliaries (6 and 14), suggesting that efficient desymmetrisation
required not only a stereogenic centre directly attached to the hy-
droxyl group, but also a large aromatic group attached to the
stereogenic centre, as use of ()-myrtenol resulted in no asym-
metric induction (Table 1, entry 4).
Table 1
Solvent-free desymmetrisation of dialdehyde 3 with chiral alcohols 6, 10e14
Entry R*OH Products (%)a de (%)
1 (þ)-(R)-6 6a (12.3), 6b (0.6) 92
2 ()-(1R,2S,5R)-10 10a (2.5), 10c (0.4) 72
3 ()-(R)-11 11a (2.0), 11c (0.5) 60
4 ()-12 12a (2.0), 12c (2.0) 0
5 ()-(1R,2S,5R)-13 13a (2.0), 13c (0.6) 54
6 (þ)-(R)-14 (þ)-14a (14.7), (þ)-14b (0.3) 96
a Yields obtained after chromatographic purification.
J.M. Botubol-Ares et al. / Tetrahedron 71 (2015) 7531e7538 7533Stereochemistries of the compounds 10ae14a, 10ce13c and
14b were established by a combination of NOESY studies, analysis
of 1H NMR coupling constants and comparison with related lac-
tones 6a, 6b, 7a and 7c, whose absolute stereochemistries haveTable 2
1H NMR spectroscopic data for 6a, 6b, 7a, 14a and 14ba
Position 6a20 7a20 14a
dH (mult, J in Hz) dH (mult, J in Hz) dH (mul
3 a: 2.47 (dd, 5.6, 17.2)
b: 2.76 (dd, 4.8, 17.2)
a: 2.50 (dd, 5.6, 17.2)
b: 2.85 (ddd, 1.2, 4.8, 17.2)
a: 2.47
b: 2.78
4 4.33 (m) 4.44 (m) 4.35 (m
5 a: 1.94 (ddd, 3.6, 5.6, 13.8)
b: 1.85 (ddd, 3.6, 6.8, 13.8)
a: 2.13 (dddd, 1.2, 3.8,
4.8, 14.0)




6 5.25 (dd, 3.6, 5.6) 5.37 (dd, 3.8, 4.8) 5.29 (dd
Si(CH3)(CH3) 0.02b (s) 0.04b (s) 0.00b (s
Si(CH3)(CH3) 0.03b (s) 0.00b (s) 0.07b
SiC(CH3)3 0.76 (s) 0.79 (s) 0.68 (s)
20 7.36e7.28 (m) 7.44e7.36 (m) 7.50e7
30 7.36e7.28 (m) 7.44e7.36 (m) 7.85e7
40 7.36e7.28 (m) 7.44e7.36 (m) d
50 7.36e7.28 (m) 7.44e7.36 (m) d
60 7.36e7.28 (m) 7.44e7.36 (m) 7.74 (s)
70 and 100 d d 7.85e7
80 and 90 d d 7.50e7
CH3OCO d 3.69 (s) d
ArCH(CH3)O 1.46 (d, 6.6) d 1.55 (d,
ArCHO 4.99 (q, 6.6) 5.32 (s) 5.15 (q,
a Chemical shift values, d, are in ppm, and the coupling constants, J, are in Hz (parenth
b Interchangeable signals.
Table 3
1H NMR spectroscopic data for 10ae13aa
Position 10a 11a
dH (mult, J in Hz) dH (mult, J in Hz)
3 a: 2.35 (dd, 6.8, 17.2)
b: 2.77 (ddd, 0.8, 5.6 17.2)
a: 2.48 (dd, 5.6, 17.
b: 2.76 (ddd, 0.8, 5.
4 4.30 (m) 4.35 (m)




6 5.50 (t, 4.0) 5.54 (dd, 3.8, 5.0)
Si(CH3)(CH3) 0.00 (s) 0.07 (s)
Si(CH3)(CH3) 0.00 (s) 0.07 (s)
SiC(CH3)3 0.82 (s) 0.88e0.85 (m)
CH(H)O d d
CH(H)O d d
CH(CH3)O d 3.92 (sext, 6.4)
CH(CH3)O d 1.13 (d, 6.4)
10 3.68 (dt, 4.2, 10.8) a: 1.44e1.36 (m)
b: 1.54e1.48 (m)
20 2.06e1.91 (m) 1.32e1.20 (m)
30 a: 1.48e1.24 (m)
b: 1.64e1.54 (m)
1.32e1.20 (m)
40 1.48e1.24 (m) 1.32e1.20 (m)
50 1.64e1.54 (m) 1.32e1.20 (m)been reported before.21 For example, compound (þ)-14a pre-
sented spectroscopic data closely related to those for compound
6a, but significantly different to those for compounds 6b and 7c,
while compound 14b presented spectroscopic data closely re-
lated to those for compound 6b. Such correlations and the NOE.
enhancement observed between H-6 and H-4 for 14b allowed us
to assign their structures as (4R,6S)-4-((tert-butyldimethylsilyl)
oxy)-6-((R)-1-(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-
one (þ)-14a and (4S,6S)-4-((tert-butyldimethylsilyl)oxy)-6-((R)-
1-(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-one (þ)-14b,
respectively (1H NMR data for compounds 6a,b, 7a, 10ae14a and
14b are presented in Tables 2 and 3; 1H NMR data for compounds
7c and 10ce13c in Table 4; 13C NMR data for compounds 6a,b, 7a,
10ae14a, 14b, 7c and 10ce13c in Tables S1eS3 of Supplementary
data).6b20 14b
t, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz)
(dd, 5.6, 17.4)
(ddd, 0.8, 4.8, 17.4)
a: 2.51 (dd, 9.2, 16.8)
b: 2.69 (ddd, 1.8, 5.4, 16.8)
a: 2.51 (dd, 9.2, 17.4)
b: 2.69 (ddd, 1.6, 5.6, 17.4)
) 3.98, tt (5.4, 9.2) 3.95 (tt, 5.6, 9.2)
ddd, 3.6, 7.0, 13.8)
(dddd, 0.8, 4.0,
8)
a 1.82 (ddd, 7.7, 9.2, 14.0)
b: 2.22 (dddd, 1.8, 4.4,
5.4, 14.0)
a: 1.85 (ddd, 7.6, 9.2, 14.0)
b: 2.21 (dddd, 1.6, 4.4,
5.6, 14.0)
, 3.6, 5.4) 5.04 (dd, 4.4, 7.7) 5.06 (dd, 4.4, 7.6)
) 0.03b (s) 0.01 (s)
(s) 0.03b (s) 0.01 (s)
0.86 (s) 0.85 (s)
.42 (m) 7.38e7.28 (m) 7.52e7.44 (m)
.81 (m) 7.38e7.28 (m) 7.87e7.78 (m)
7.38e7.28 (m) d
7.38e7.28 (m) d
7.38e7.28 (m) 7.74 (s)
.81 (m) d 7.87e7.78 (m)
.42 (m) d 7.52e7.44 (m)
d d
6.6) 1.47, d (6.6) 1.56 (d, 6.4)
6.6) 5.08, q (6.6) 5.18 (q, 6.4)
eses).
12a 13a
dH (mult, J in Hz) dH (mult, J in Hz)
4)
0, 17.4)
a: 2.48 (dd, 5.6, 17.6)
b: 2.75 (ddd, 0.8, 4.8, 17.6)
a: 2.47 (dd, 6.0, 17.2)
b: 2.76 (ddd, 0.8, 5.2, 17.2)





5.45 (dd, 4.0, 4.8) 5.62 (t, 4.2)
0.06 (s) 0.07 (s)
0.06 (s) 0.07 (s)
0.86 (s) 0.89e0.70 (m)
4.15 (dd, 1.4, 12.2) d
4.05 (dd, 1.4, 12.2) d
d d
d d
2.14e2.08 (m) 3.64 (dt, 4.4, 10.6)
d 1.24e1.14 (m)
5.54 (m) a: 1.02e0.92 (m)
b: 1.68e1.54 (m)
2.27 (m) a: 0.89e0.70 (m)
b: 1.68e1.54 (m)
2.14e2.08 (m) 1.40e1.28 (m)
(continued on next page)
Table 3 (continued )
Position 10a 11a 12a 13a
dH (mult, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz)
60 a: 0.84e0.78 (m)
b: 2.06e1.91 (m)
0.88e0.85 (m) d a: 0.89e0.70 (m)
b: 2.03e1.96 (m)
70 d d a: 1.12 (d, 8.8)
b: 2.39 (dt, 5.6, 8.8)
d
C20C(CH3)]C(H)(H) 1.60 (s) d d d
C20C(CH3)]C(H)(H) 4.66 (br s) d d d
C20C(CH3)]C(H)(H) 4.67 (br s) d d d
C20CH(CH3)(CH3) d d d 0.89e0.70 (m)
C20CH(CH3)(CH3) d d d 0.78 (d, 6.8)
C50-(CH3)(CH3) d d 0.81b (s) d
C50-(CH3)(CH3) d d 1.28b (s) d
C50-CH3 0.89 (d, 6.8) d d 0.88 (d, 6.8)
a Chemical shift values, d, are in ppm, and the coupling constants, J, are in Hz (parentheses).
b Interchangeable signals.
Table 4
1H NMR spectroscopic data for 7c and 10ce13ca
Position 7c20 10c 11c 12c 13c
dH (mult, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz) dH (mult, J in Hz)
3 a: 2.49 (dd, 4.8, 17.3)
b: 2.70 (dd, 4.8, 17.3)
a: 2.45 (dd, 5.2, 17.2)
b: 2.69 (dd, 5.2, 17.2)
a: 2.48 (dd, 5.2, 17.2)
b: 2.74 (dd, 5.2, 17.2)
a: 2.48 (dd, 5.2, 17.2)
b: 2.75 (dd, 5.2, 17.2)
a: 2.48 (dd, 5.0, 17.2)
b: 2.73 (dd, 5.0, 17.2)
4 4.36 (quint, 4.8) 4.29 (quint, 5.2) 4.33 (quint, 5.2) 4.34 (quint, 5.2) 4.33 (quint, 5.0)
5 2.16 (t, 4.8) 1.91e1.87 (m) 1.96 (m) 1.98e1.94 (m) 2.04e1.94 (m)
6 5.64 (t, 4.6) 5.42 (dd, 4.2, 5.2) 5.52 (dd, 4.6, 5.2) 5.46 (t, 4.4) 5.50 (t, 5.0)
Si(CH3)(CH3) 0.08b (s) 0.05 (s) 0.07 (s) 0.06 (s) 0.07 (s)
Si(CH3)(CH3) 0.07b (s) 0.05 (s) 0.07 (s) 0.06 (s) 0.07 (s)
SiC(CH3)3 0.87 (s) 0.86 (s) 0.90e0.85 (m) 0.86 (s) 0.91e0.80 (m)
CH(H)O d d d 4.20 (dd, 1.6, 12.8) d
CH(H)O d d d 4.17 (dd, 1.6, 12.8) d
CH(CH3)O d d 3.83 (sext, 6.0) d d
CH(CH3)O d d 1.21 (d, 6.4) d d
ArCHO 5.47 (s) d d d d
10 d 3.60 (dt, 4.4, 10.2) a: 1.44e1.36 (m)
b: 1.54e1.46 (m)
d 3.45 (dt, 4.8, 10.8)
20 7.44e7.32 (m) 1.96 (ddd, 3.6, 10.2, 12.8) 1.30e1.24 (m) 2.12e2.08 (m) 1.26e1.18 (m)
30 7.44e7.32 (m) a: 1.32 (m)
b: 1.66e1.57 (m)
1.30e1.24 (m) 5.52 (m) a: 1.05e0.92 (m)
b: 1.65e1.58 (m)
40 7.44e7.32 (m) a: 0.88e0.85 (m)
b: 1.66e1.57 (m)
1.30e1.24 (m) 2.27 (m) a: 0.91e0.80 (m)
b: 1.65e1.58 (m)
50 7.44e7.32 (m) 1.50e1.41 (m) 1.30e1.24 (m) 2.12e2.08 (m) 1.42e1.33 (m)
60 7.44e7.32 (m) a: 1.02 (m)
b: 2.14e2.09 (m)
0.90e0.85 (m) d a: 1.05e0.92 (m)
b: 2.22e2.16 (m)
70 d d d a: 1.15 (d, 8.8)
b: 2.38 (dt, 5.6, 8.8)
d
C20C(CH3)]CH2 d 1.70 (s) d d d
C20C(CH3)]C(H)(H) d 4.76 (br s) d d d
C20C(CH3)]C(H)(H) d 4.78 (br s) d d d
C20CH(CH3)(CH3) d d d d 0.91e0.80 (m)
C20CH(CH3)(CH3) d d d d 0.77 (d, 7.2)
C20CH(CH3)(CH3) d d d d 2.04e1.94 (m)
C50e(CH3)(CH3) d d d 1.26b (s) d
C50e(CH3)(CH3) d d d 0.81b (s) d
C50eCH3 d 0.90 (d, 6.4) d d 0.91e0.80 (m)
CH3COO 3.70 (s) d d d d
a Chemical shift values, d, are in ppm, and the coupling constants, J, are in Hz (parentheses).
b Interchangeable signals.
J.M. Botubol-Ares et al. / Tetrahedron 71 (2015) 7531e753875342.2. Preparation of nor-mevalonic acid lactones (L)-(R)-4 and
(D)-(S)-5
To exemplify the utility of our methodology, and in order to
prepare reference compounds for SAR studies,18 an enantioselective
synthesis of nor-mevalonic acid lactones ()-(R)-4 and (þ)-(S)-
513e,22 was undertaken from lactones (þ)-14a and ()-15a (Scheme
4), which were in turn obtained from dialdehyde 3 (Schemes 2 and
3). Treatment of lactone (þ)-14awith MeONa and MeOH at 35 C
yielded ()-(R)-8 in 52% yield and 99% ee.23 Reduction of ()-(R)-8with NaBH4 at 35 C to yield ()-(R)-1624 and subsequent lacto-
nisation with PTSA25 produced the corresponding lactone ()-(R)-
17 that was subsequently treated with TBAF/AcOH,26 affording (R)-
nor-mevalonic acid lactone (()-(R)-4) in 70% yield and 79% ee.23,27
Desymmetrisation of the dialdehyde 3with ()-(S)-1-(naphthalen-
2-yl)ethanol afforded the corresponding lactone ()-15a in 14.7%
overall yield and 96% de (Scheme 3); methanolysis of which, re-
duction with NaBH4, lactonisation25 to yield (þ)-(S)-19 and depro-
tection with TBAF/AcOH,25 yielded (S)-nor-mevalonic acid lactone
((þ)-(S)-5) in 67% overall yield and 96% ee.23
Scheme 4. Preparation of (R) and (S) nor-mevalonic acid lactones (()-(R)-4) and
((þ)-(S)-5).
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In summary, the optimization of the desymmetrisation of meso
dialdehyde 3 led to the selective preparation of (þ)-(4R,6S)-4-
((tert-butyldimethylsilyl)oxy)-6-((R)-1-(naphthalen-2-yl)ethoxy)
tetrahydro-2H-pyran-2-one (14a) and (4S,6R)-4-((tert-butyldime-
thylsilyl)oxy)-6-((S)-1-(naphthalen-2-yl)ethoxy)tetrahydro-2H-
pyran-2-one-(15a) in 96% dewhen either (R)-(þ)-1-(naphthalen-2-
yl)ethanol or (S)-()-1-(naphthalen-2-yl)ethanol was used under
solvent-free conditions at room temperature. HPLC purification and
methanolysis of (þ)-(4R,6S,10R)-(14a) or ()-(4S,6R,10S)-(15a) yiel-
ded ()-(R)-methyl 3-(tert-butyldimethylsilyloxy)-5-oxopen-
tanoate ()-(R)-(8) and (þ)-(S)-methyl 3-(tert-butyldimethylsily-
loxy)-5-oxopentanoate (þ)-(S)-(9), respectively, in 99% ee. Further
transformation of these substrates allowed the enantioselective
preparation of the nor-mevalonic acid lactones ()-(R)-4 and
(þ)-(S)-5 (in 42% overall yield and 79% ee and in 41% overall yield
and 96% ee, respectively).4. Experimental section
4.1. General
Unless otherwise noted, materials and reagents were obtained
from commercial suppliers and were used without further purifi-
cation. Dichloromethane was freshly distilled from CaH2 and tet-
rahydrofuran was dried over sodium and benzophenone andfreshly distilled before use. Air- and moisture-sensitive reactions
were performed under an argon atmosphere. Purification by semi-
preparative and analytical HPLC was performed, respectively, with
250 mm10 mm (10 mm particles) and 250 mm4 mm (5 mm
particles) columns using a differential refractometer detector. Silica
gel was used for column chromatography. TLC analyses were per-
formed on aluminium plates coated with silica gel with fluorescent
indicator (254 nm), 0.25 mm thick. Enantiomeric excesses (ee)
were measured by GC using a Cyclosil B chiral column (30 m
length0.25 mm ID, 0.25 mm film thickness), using an FID detector
at 320 C, a split injector (15:1 ratio) at 250 C, hydrogen as carrier
at 10 psi and 1 mL of injection volume. Temperature program is
described in the experimental section for every relevant com-
pound. Specific rotations were determined with a digital polarim-
eter. Infrared spectra were recorded on an FTIR spectrophotometer
and peak position reported in wavenumbers (cm1). 1H spectra
were recorded on spectrometers operating at 300 and 400MHz. 13C
NMR spectra were measured at 75 and 100 MHz with complete
proton decoupling. Chemical shifts were referenced to CDCl3 (dH
7.25, dC 77.0). NMR assignments were made by combination of 1D
and 2D techniques. Multiplicities are described using the following
abbreviations: s¼singlet, d¼doublet, t¼triplet, q¼quartet;
quint¼quintet; sext¼sextet; m¼multiplet, br¼broad. High-
resolution mass spectrometry (HRMS) was recorded with a dou-
ble-focussing magnetic sector mass spectrometer in positive ion
mode, or in a QTOF mass spectrometer in positive ion electrospray
mode at 20 V cone voltage.
4.2. Procedures
4.2.1. General procedure for the preparation of 6-alkyloxy-4-(tert-
butyldimethylsilyloxy)tetrahydro-2H-pyran-2-ones (6a,b, 10ae15a,
14b, 15b and 10ce13c): desymmetrisation of 3-(tert-butyldime-
thylsilyloxy)pentanedial (3) under solvent-free conditions followed by
PCC oxidation. The requisite alcohol (see Schemes 2 and 3 of the
manuscript) (2.9 mmol) was added to a mixture of 3-(tert-butyl-
dimethylsilyloxy)pentanedial (3) (1 mmol)20 and 4 A molecular
sieves (0.5 g for each mmol of 3) under an argon atmosphere and
the mixture stirred for 24 h. The slurry was dissolved in CH2Cl2
(20mL) and added dropwise to a suspension of PCC (3.5 mmol) and
powdered molecular sieves 4A (twice the weight of the alcohol) in
dichloromethane (70 mL) at room temperature. The reaction mix-
ture was stirred vigorously for 18 h, diethyl ether was then added
(200 mL) and the mixture was stirred for a further 1 h. The sus-
pensionwas filtered through a pad of silica gel and washed through
with a further quantity of ether (200 mL). The ether was removed
under reduced pressure to give the crude mixture of tetrahydro-
2H-pyran-2-ones, which was purified by column chromatography
(petroleum ether/Et2O, 90:10), to yield the corresponding tetrahy-
dro-2H-pyran-2-ones in the ratios and yields shown below and in
Table 1 and Schemes 2 and 3 of the manuscript.
4.2.1.1. ()-(4R(S),6S(R))-4-((tert-Butyldimethylsilyl)oxy)-6-
(((1R,2S,5R)-5-methyl-2-(prop-1-en-2-yl)cyclohexyl)oxy)tetrahydro-
2H-pyran-2-one (10a). Yield 9.5 mg, 2.5%. Colourless oil; HPLC
tR¼21 min (petroleum ether/ethyl acetate 93:7; flow¼3.0 mL/min);
[a]D20 73.7 (c 0.1, CHCl3); IR (film) nmax 3073, 2932, 2858, 1749,
1644, 1453, 1378, 1228, 1145, 1024, 889, 837, 781 cm1; 1H NMR
(CDCl3, 400 MHz) (see Table 3); 13C NMR (CDCl3, 100 MHz) (see




2H-pyran-2-one (10c). Yield 1.5 mg, 0.4%. Colourless oil; HPLC
tR¼26min (petroleum ether/ethyl acetate 93:7; flow¼3.0 mL/min);
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1647, 1458, 1378, 1256, 1153, 1006, 837, 778 cm1; 1H NMR
(400 MHz, CDCl3) (see Table 4); 13C NMR (100 MHz, CDCl3) (see
Table S3); HRMS (CIþ): m/z [MþH]þ, found 383.2605. C21H39O4Si
requires 383.2618.
4.2.1.3. ()-(4R(S),6S(R))-4-((tert-Butyldimethylsilyl)oxy)-6-((R)-
octan-2-yloxy)tetrahydro-2H-pyran-2-one (11a). Yield 7.2 mg, 2%.
Colourless oil; HPLC tR¼19 min (petroleum ether/ethyl 93:7;
flow¼3.0 mL/min); [a]D20 44.9 (c 0.1, CHCl3); IR (film) nmax 2930,
2858, 1751, 1464, 1256, 1103, 1008, 837, 778 cm1; 1H NMR
(400 MHz, CDCl3) (see Table 3); 13C NMR (100 MHz, CDCl3) (see
Table S2); HRMS (CIþ): m/z [MþH]þ, found 359.2625. C19H39O4Si
requires 359.2618.
4.2.1.4. ()-(4S(R),6R(S))-4-((tert-butyldimethylsilyl)oxy)-6-((R)-
octan-2-yloxy)tetrahydro-2H-pyran-2-one (11c). Yield 1.8 mg, 0.5%.
Colourless oil; HPLC tR¼27 min (petroleum ether/ethyl acetate
93:7; flow¼3.0 mL/min); [a]D20 28.3 (c 0.2, CHCl3); IR (film) nmax
2932, 2857, 1748, 1469, 1256, 1103, 1021, 838, 778 cm1; 1H NMR
(400 MHz, CDCl3) (see Table 4); 13C NMR (100 MHz, CDCl3) (see




dro-2H-pyran-2-one (12a). Yield 7.6 mg, 2%. Colourless oil; HPLC
tR¼40min (petroleum ether/ethyl acetate 94:6; flow¼0.8 mL/min);
[a]D20 þ40.0 (c 0.2, CHCl3); IR (film) nmax 2929, 2858, 1753, 1472,
1383, 1225, 1102, 1030, 838, 778 cm1; 1H NMR (400 MHz, CDCl3)
(see Table 3); 13C NMR (100 MHz, CDCl3) (see Table S2); HRMS
(CIþ): m/z [MþH]þ, found 381.2455. C21H37O4Si requires 381.2461.
4.2.1.6. ()-(4S(R),6R(S))-4-((tert-Butyldimethylsilyl)oxy)-6-
(((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)methoxy)tetrahy-
dro-2H-pyran-2-one (12c). Yield 7.6 mg, 2%. Colourless oil; HPLC
tR¼37min (petroleum ether/ethyl acetate 94:6; flow¼0.8 mL/min);
[a]D20 129.0 (c 0.1, CHCl3); IR (film) nmax 2932, 2858, 1752, 1469,
1369, 1256, 1103, 1023, 838, 777 cm1; 1H NMR (400 MHz, CDCl3)
(see Table 4); 13C NMR (100 MHz, CDCl3) (see Table S3); HRMS
(CIþ): m/z [MþH]þ, found 381.2453. C21H37O4Si requires 381.2461.
4.2.1.7. ()-(4R(S),6S(R))-4-((tert-Butyldimethylsilyl)oxy)-6-
(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)tetrahydro-2H-py-
ran-2-one (13a). Yield 7.7 mg, 2%. Colourless oil; HPLC tR¼16 min
(petroleum ether/ethyl acetate 93:7; flow¼3.0 mL/min); [a]D20
67.7 (c 0.15, CHCl3); IR (film) nmax 2929, 2858, 1753, 1463, 1369,
1255, 1101, 1023, 838, 777 cm1; 1H NMR (400 MHz, CDCl3) (see
Table 3); 13C NMR (100MHz, CDCl3) (see Table S2); HRMS (CIþ):m/z
[MþH]þ, found 385.2764. C21H41O4Si requires 385.2774.
4.2.1.8. (þ)-(4S(R),6R(S))-4-((tert-Butyldimethylsilyl)oxy)-6-
(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)tetrahydro-2H-py-
ran-2-one (13c). Yield 2.3 mg, 0.6%. Colourless oil; HPLC tR¼21 min
(petroleum ether/ethyl acetate 93:7; flow¼3.0mL/min); [a]D20þ21.1
(c 0.1, CHCl3); IR (film) nmax 2930, 2859,1752,1464,1369,1253,1104,
1013, 837, 778 cm1; 1H NMR (400 MHz, CDCl3) (see Table 4); 13C
NMR (100 MHz, CDCl3) (see Table S3); HRMS (CIþ): m/z [MþH]þ,
found 385.2766. C21H41O4Si requires 385.2774.
4.2.1.9. (þ)-(4R,6S)-4-((tert-Butyldimethylsilyl)oxy)-6-((R)-1-
(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-one (14a). Yield
58.8 mg, 14.7%. Colourless oil; HPLC tR¼42 min (petroleum ether/
ethyl acetate 93:7; flow¼3.0 mL/min); [a]D20þ118.0 (c 1.0, CHCl3); IR
(film) nmax 3060, 2955, 2858, 1749, 1471, 1382, 1231, 1100, 837,
749 cm1; 1H NMR (400 MHz, CDCl3) (see Table 2); 13C NMR(100 MHz, CDCl3) (see Table S1); HRMS (ESI-QTOF): m/z [MþNa]þ,
found 423.1968. C23H32O4NaSi requires 423.1968; [MþH
C6H15SiOH]þ, found 269.1161. C17H17O3 requires 269.1178.
4.2.1.10. (þ)-(4S,6S)-4-((tert-Butyldimethylsilyl)oxy)-6-((R)-1-
(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-one (14b). Yield
1.2mg, 0.3%. Colourless oil; HPLC tR¼34min (petroleum ether/ethyl
acetate 93:7; flow¼3.0 mL/min); [a]D20 þ91.4 (c 1.4, CHCl3); IR (film)
nmax 3056, 2955, 2858, 1749, 1462, 1378, 1255, 1095, 1027, 837,
778 cm1; 1H NMR (400 MHz, CDCl3) (see Table 2); 13C NMR
(100 MHz, CDCl3) (see Table S1); HRMS (ESI-QTOF): m/z [MþNa]þ,
found 423.1968. C23H32O4NaSi requires 423.1968;
[MþHC6H15SiOH]þ, found 269.1175. C17H17O3 requires 269.1178.
4.2.1.11. ()-(4S,6R)-4-((tert-Butyldimethylsilyl)oxy)-6-((S)-1-
(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-one (15a). Yield
58.7 mg, 14.7%. [a]D20 118.0 (c 1.0, CHCl3).
4.2.1.12. ()-(4R,6R)-4-((tert-Butyldimethylsilyl)oxy)-6-((S)-1-
(naphthalen-2-yl)ethoxy)tetrahydro-2H-pyran-2-one (15b). Yield
1.3 mg, 0.3%. [a]D20 91.4 (c 1.3, CHCl3).
4.2.2. Preparation of ()-(R)-Methyl 3-(tert-butyldimethylsilyloxy)-
5-oxopentanoate (()-(R)-8). Sodium methoxide (654.5 mg,
12.12mmol) was added to a solution of tetrahydro-2H-pyran-2-one
(þ)-14a (809.0 mg, 2.02 mmol) in dry MeOH (101 mL) at 35 C.
The reaction mixture was stirred at 35 C for 24 h, then quenched
with saturated NH4Cl (110 mL). The mixture was then allowed to
warm to room temperature and diethyl ether (300 mL) was added.
The layers were separated and the aqueous phase was further
extracted with diethyl ether (3300 mL). The combined organic
layers were washed with brine (2500 mL), dried over Na2SO4 and
the solvent was removed under reduced pressure to give a crude
reaction product, which was purified by column chromatography
(petroleum ether/Et2O 90:10) to give (R)-1-phenylethanol
(157.0 mg, 64%) and ()-(R)-8 (275.0 mg, 52%, 99% ee) as a colour-
less oil; [a]D20 10.2 (c 0.3, CHCl3); IR (film) nmax 2931, 2898, 2857,
1736, 1438, 1255, 1087, 837, 777 cm1; 1H NMR (400 MHz, CDCl3)
d 9.75 (1H, t, J¼2.0 Hz), 4.59 (1H, quint, J¼6.2 Hz), 3.63 (3H, s),
2.67e2.62 (2H, m), 2.52 (2H, m), 0.80 (9H, s), 0.03 (6H, s); 13C NMR
(100 MHz, CDCl3) d 200.8, 171.1, 64.9, 51.6, 50.8, 42.3, 25.5 (3C), 17.8,
4.9 (2C); HRMS (CIþ): m/z [MCH3]þ, found 245.1199. C11H21O4Si
requires 245.1209. The enantiomeric excess of 8 could be de-
termined by chiral gas chromatography, using the general condi-
tions stated above; isocratic 80 C. tR (min): 251.36.
4.2.3. Preparation of (þ)-(S)-methyl 3-(tert-butyldimethylsilyloxy)-
5-oxopentanoate ((þ)-(S)-9). Compound ()-15a (660.0 mg,
1.65 mmol) was converted into (þ)-(S)-methyl 3-(tert-butyldime-
thylsilyloxy)-5-oxopentanoate ((þ)-(S)-9) (220.0 mg, 50%, 99% ee)
following the methodology described above for the synthesis of
()-(R)-8 from (þ)-14a. Colourless oil; [a]D20 þ10.2 (c 0.25, CHCl3).
The enantiomeric excess of 9 could be determined by chiral gas
chromatography, using the general conditions stated above; iso-
cratic 80 C. tR (min): 256.19.
4.2.4. Preparation of ()-(R)-methyl 3-(tert-butyldimethylsilyloxy)-
5-hydroxypentanoate ((R)-16). Sodium borohydride (28.5 mg,
0.75 mmol) was added to a solution of (R)-8 (153.7 mg, 0.59 mmol)
in dry MeOH (101 mL) at 35 C under an argon atmosphere. The
reaction mixture was stirred at 35 C for 24 h, adding two sup-
plementary portions of NaBH4 (15 mg each portion). Then, 1 M HCl
was added until pH 7 (8 mL) and the reaction mixture was allowed
towarm to room temperature. Solvent was removed under reduced
pressure and ethyl acetate (50 mL) and brine (15 mL) were added.
The layers were separated and the aqueous layer was further
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layers werewashedwith brine (100mL), dried over Na2SO4, filtered
and the solvent was removed under reduced pressure to give the
crude reaction product, which was purified by column chroma-
tography (petroleum ether/EtOAc 90:10) to give (R)-16 (106.7 mg,
69%) and (R)-4-((tert-butyldimethylsilyl)oxy)tetrahydro-2H-pyran-
2-one (R)-17 (12.4 mg, 9%). Data for (R)-16: colourless oil; [a]D202.0
(c 3.1, CHCl3); IR (film) nmax 3422, 2930, 1741, 1438, 1257, 1161, 1026,
837, 777 cm1; 1H NMR (400 MHz, CDCl3) d 4.30 (1H, ddt, J¼12.4,
6.4, 4.8 Hz), 3.76e3.66 (2H, m), 3.64 (3H, s), 2.53 (2H, dd, J¼17.6,
6.4 Hz), 2.47 (2H, dd, J¼17.6, 6.4 Hz), 2.42 (s, OH), 1.85e1.65 (2H, m),
0.84 (9H, s), 0.07 (3H, s), 0.04 (3H, s); 13C NMR (100 MHz, CDCl3)
d 171.8, 68.0, 59.4, 51.5, 42.1, 38.9, 25.6 (3C), 17.8, 4.8, 4.9; HRMS
(CIþ): m/z [MC(CH3)3]þ, found 205.0899. C8H17O4Si requires
205.0896.
4.2.5. Preparation of (þ)-(S)-methyl 3-(tert-butyldimethylsilyloxy)-
5-hydroxypentanoate ((S)-18). (þ)-(S)-Methyl 3-(tert-butyldime-
thylsilyloxy)-5-oxopentanoate ((S)-9) (110.0 mg, 0.42 mmol) was
converted into (þ)-(S)-methyl 3-(tert-butyldimethylsilyloxy)-5-
hydroxypentanoate ((S)-18) (85.0 mg, 72%) and (S)-19 (7.0 mg,
7%) following themethodology described above for the synthesis of
(R)-16 from (R)-8. Data for (S)-18: colourless oil; [a]D20 þ2.0 (c 0.2,
CHCl3).
4.2.6. Preparation of ()-(R)-4-((tert-butyldimethylsilyl)oxy)tetra-
hydro-2H-pyran-2-one ((R)-17). p-Toluenesulfonic acid mono-
hydrate (PTSA) (1.8 mg, 0.01 mmol) was added to a solution of
()-(R)-methyl 3-(tert-butyldimethylsilyloxy)-5-
hydroxypentanoate ((R)-16) (38.0 mg, 0.15 mmol) in dry CH2Cl2
(2.3 mL) at room temperature. When TLC analysis indicated the
completion of the reaction (1 h), saturated NaHCO3 was added
(3 mL) and the mixture was stirred for a further 15 min. The
aqueous phase was then extracted with ethyl acetate (325 mL),
the combined organic layers werewashedwith brine (50mL), dried
over Na2SO4 and filtered. Evaporation of the solvent gave the crude
product that was purified by silica gel column chromatography
(petroleum ether/EtOAc 90:10), to yield (R)-17 (28.9 mg, 87%, 89%
ee). Colourless oil; [a]D20 2.8 (c 0.1, CHCl3); IR (film) nmax 2930,
2857, 1739, 1472, 1260, 1161, 1085, 837, 778 cm1; 1H NMR
(300 MHz, CDCl3) d 4.56 (1H, ddd, J¼11.2, 9.6, 3.9 Hz), 4.30e4.22
(2H, m), 2.69 (1H, dd, J¼17.4, 5.0 Hz), 2.52 (1H, dd, J¼17.4, 4.2 Hz),
2.05e1.94 (1H, m), 1.83e1.73 (1H, m), 0.86 (9H, s), 0.06 (3H, s), 0.05
(3H, s); 13C NMR (75 MHz, CDCl3) d 170.0, 65.3, 63.9, 40.0, 31.3, 25.6
(3C), 18.0, 4.8, 4.9; HRMS (CIþ): m/z [MC(CH3)3]þ, found
173.0645. C7H13O3Si requires 173.0634. The enantiomeric excess of
17 could be determined by chiral gas chromatography, using the
general conditions stated above; isocratic 100 C. tR (min): 244.97
(minor), 249.28 (major).
4.2.7. Preparation of (þ)-(S)-4-((tert-butyldimethylsilyl)oxy)tetra-
hydro-2H-pyran-2-one ((S)-19). (þ)-(S)-Methyl 3-(tert-butyldime-
thylsilyloxy)-5-hydroxypentanoate ((S)-18) (48.0 mg, 0.18 mmol)
was converted into (þ)-(S)-4-((tert-butyldimethylsilyl)oxy)tetra-
hydro-2H-pyran-2-one ((S)-19) (35.6 mg, 84%, 96% ee) following
the methodology described above for the synthesis of (R)-17 from
(R)-16. Colourless oil; [a]D20 þ2.9 (c 0.3, CHCl3). The enantiomeric
excess of 19 could be determined by chiral gas chromatography,
using the general conditions stated above; isocratic 100 C. tR
(min): 238.88 (major), 242.38 (minor).
4.2.8. Preparation of ()-(R)-4-hydroxytetrahydro-2H-pyran-2-one
((R)-4). ()-(R)-4-((tert-Butyldimethylsilyl)oxy)tetrahydro-2H-py-
ran-2-one ((R)-17) (27.4 mg, 0.12 mmol) was converted into
()-(R)-4-hydroxytetrahydro-2H-pyran-2-one ((R)-4) (9.7 mg, 70%,
79% ee) following the methodology described in the literature.20Colourless oil; [a]D20 3.1 (c 0.34, CHCl3); IR (film) nmax 3422,
2926, 2875, 1719, 1458, 1383, 1261, 1079 cm1; 1H NMR (400 MHz,
CDCl3) d 4.57 (1H, ddd, J¼11.4, 8.0, 4.0 Hz), 4.34 (1H, quint,
J¼5.2 Hz), 4.28 (1H, ddd, J¼11.4, 6.4, 4.8 Hz), 2.82 (1H, dd, J¼17.6,
5.2 Hz), 2.58 (1H, ddd, J¼17.6, 5.2, 1.0 Hz), 2.12 (1H, m), 1.89 (1H, m),
1.64 (s, OH); 13C NMR (100 MHz, CDCl3) d 170.0, 65.2, 63.4, 39.4,
31.0; HRMS (CIþ): m/z [M]þ, found 116.0475. Calcd for C5H8O3
116.0473. The enantiomeric excess of 4 could be determined by
chiral gas chromatography, using the general conditions stated
above; isocratic 100 C. tR (min): 208.23 (minor), 211.67 (major).
4.2.9. Preparation of (þ)-(S)-4-hydroxytetrahydro-2H-pyran-2-one
((S)-5). (þ)-(S)-4-((tert-Butyldimethylsilyl)oxy)tetrahydro-2H-py-
ran-2-one ((S)-19) (31.1 mg, 0.14 mmol) was converted into (þ)-(S)-
4-hydroxytetrahydro-2H-pyran-2-one ((S)-5) (10.5 mg, 67%, 96%
ee) following the methodology described in the literature.20 Col-
ourless oil; [a]D20 þ3.6 (c 0.2, CHCl3). The enantiomeric excess of 5
could be determined by chiral gas chromatography, using the
general conditions stated above; isocratic 100 C. tR (min): 204.26
(major), 217.71 (minor).Acknowledgements
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